FDA Approves New Treatment for Cluster Headache

Health and Medical

The US Food and Drug Administration (FDA) approved a new injection today "Emgality" It contains active ingredient (galcanezumab-gnlm) For the treatment of accidental cluster headaches in adults.

"Said Eric Pastings, deputy director of nerve products at the FDA "FDA": "Availability of Injection Emgality For patients the first FDA approved treatment (FDA) Reduces the frequency of transient cluster headache episodes, which is often very painful and debilitating. "

He continued: "The FDA is committed FDA To continue working with drug developers to provide treatments to meet unmet medical needs of patients. "

Cluster headaches are defined as a form of headache that produces severe pain, often at the same time every day, for several weeks to months. Symptoms of the headache may include: eyes with blood, severe eye tear, eyelid drooping, runny nose and / or nasal congestion, People suffer from insomnia and stress.

Cluster headache attacks can occur several times a day, usually lasting between 15 minutes and three hours.

Proved effective Emgality In the treatment of cross-cluster headache in a clinical trial, the drug was compared with placebo in 106 patients.

They are given Emgality By self-injection of the patient, it was first approved by the Food and Drug Administration in September 2018 for the treatment of migraine in adults. It is the most important side effect to inject "Emgality" Allergy is against drug derivatives.

(tagsToTranslate) FDA (t) Cluster headaches (t) Treatment of cluster headaches (t) Headache treatment